IDH1 and acute myeloid leukemia: Enasidenib (IDHIFA®, AG-221, Celgene Corporation) was the first IDH inhibitor approved by the Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R/R) AML with IDH2 mutation [201].